Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 1;103(44):e40418.
doi: 10.1097/MD.0000000000040418.

Recovery of gastrointestinal functional after surgery for abdominal tumors: A narrative review

Affiliations
Review

Recovery of gastrointestinal functional after surgery for abdominal tumors: A narrative review

Gui-Sheng Xie et al. Medicine (Baltimore). .

Abstract

Postoperative gastrointestinal dysfunction, including temporary nonmechanical suppression of gastrointestinal motility (known as postoperative ileus), occurs in about 10% surgeries of abdominal tumors. Since these complications can prolong hospitalization and affect eating, it is important to understand their risk factors and identify effective interventions to manage or prevent them. The present review comprehensively examined the relevant literature to describe risk factors for postoperative ileus and effective interventions. Risk factors include old age, open surgery, difficulty of surgery, surgery lasting longer than 3 hours, preoperative bowel treatment, infection, and blood transfusion. Factors that protect against postoperative ileus include early enteral nutrition, minimally invasive surgery, and multimodal pain treatment. Interventions that can shorten or prevent such ileus include minimally invasive surgery, early enteral nutrition as well as use of chewing gum, laxatives, and alvimopan. Most of these interventions have been integrated into current guidelines for enhanced recovery of gastrointestinal function after surgery. Future high-quality research is needed in order to clarify our understanding of efficacy and safety.

PubMed Disclaimer

Conflict of interest statement

J.-H. Z received speaker fees for Bayer, BeiGene, AstraZeneca, MSD, Roche, Innovent, and HengRui. But none of them are related to this project at all. The other authors have no conflicts of interest to disclose.

Similar articles

References

    1. Woeltjen MM, Niehoff JH, Saeed S, et al. . Impact of an online reference system on the diagnosis of rare or atypical abdominal tumors and lesions. Sci Rep. 2024;14:15986. - PMC - PubMed
    1. Federica C, Gianluca F, Margherita R, et al. . Surgery for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: milestone changes in the last two decades potentially affecting current guidelines. Hepatoma Research. 2023;9:13.
    1. Gianluca C, Ho-Seong H, Boram L, Hae Won L, Jai Young C, Roberto Ivan T. The role of minimally invasive surgery in the treatment of HCC. Hepatoma Research. 2022;8:26.
    1. Samantha MR, Timothy MP. Surgical management of intrahepatic cholangiocarcinoma. Hepatoma Research. 2023;9:17.
    1. Xu LN, Li GP, Yang B. Establishment of a risk assessment system for complications of hepatectomy based on preoperative variables. iLIVER. 2022;1:217–24. - PubMed

MeSH terms